Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Divergence Raises $12 million
by Marc S. Reisch
February 23, 2009
| A version of this story appeared in
Volume 87, Issue 8
Divergence has raised $12 million from investors to advance its nematicide program. The St. Louis-based firm claims it has discovered the first new molecules to control plant parasitic nematodes, a class of pest that the firm says causes billions of dollars in crop loss annually and widespread disease in humans and animals. The 10-year-old biotechnology firm applies genomics and informatics to develop parasite controls. Working with Monsanto, Divergence last year completed the genome for the soybean cyst nematode and made it publicly available.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X